The Evaluation of the Effectiveness of Funding Treatment Programs in Rheumatology

• Autorzy: Andrzej Śliwczyński
• Języki publikacji: EN

Abstrakty

EN

Background: The public payer in Poland has been financing biological drugs in rheumatology since 2004. Until now, there have been no analyses of the influence of this type of funding on the cost level for the public payer. Financing over an 8 year period allows an objective approach towards the results. Materials and methods: Data extracted with the use of data tools reported to the National Health Fund (NFZ) by health service providers, including drugs used in a patient's therapy. For data analysis, statistic tools were used: Statistica 9 and 10 and Excel spreadsheet. Results: The number of people treated in Poland with biological drugs is approx. 5% of the potential population with rheumatoid joint inflammation diagnosis and juvenile idiopathic joint inflammation. In the analyses, the results of the Kobelt-Kasteng report have been confirmed, referring to the differences existing in Europe when it comes to therapy cost disparity. The cost of therapy in Poland increases depending on the type of therapy: infliximab (for patients up to 70kg), then rituximab and etanercept, adalimumab and infliximab (for patients over 70kg). The calculated price index and therapy cost indicates that the costs of such therapies are lower in Poland in comparison with other countries. The r-Pearson correlation factor of 0.61 to 0.73 indicates that there is an accurate balance between the number of clinics conducting the therapy and the number of patients. In the analyzed period, the budget for the rheumatology biological drug therapy increased.(original abstract)

Słowa kluczowe

EN

Financing of health protection; Health care protection; Health; Medications; Payment for medications

PL

Finansowanie ochrony zdrowia; Ochrona zdrowia; Zdrowie; Leki; Odpłatność za leki

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2013
• Numer: nr 1
• Strony: 92--109

Twórcy

autor

Andrzej Śliwczyński

• Uniwersytet Medyczny w Łodzi; Narodowy Fundusz Zdrowia

Bibliografia

• Act of August 27, 2004 on healthcare services financed from public funds (Journal of Laws of 2008 No. 164, item. 1027, as amended)
• Regulation of the Minister of Health of January 11, 2010, amending the regulation on guaranteed benefits in health care programs (Journal of Laws of 2010 No. 05, item. 29, as amended)
• Regulation of the Minister of Health of March 2, 2010, amending the regulation on guaranteed benefits in hospital treatment (Journal of Laws of 2010 No. 30, item. 157, as amended)
• Order No. 101/2007/DGL 05.11.2007, amending the order on approval of "Specific information materials on the subject of proceedings to finalise contracts for providing health care services and on performance and funding of such contracts in specific fields, such as hospital treatment"
• Order No. 65/2009/DGL of President of the National Health Fund of June 19, 2008 on conclusion conditions and performance of contracts, such as hospital treatment contracts in the scope of therapeutic health programs
• Order No. 103/2012/DSOZ of President of the National Health Fund of 24 December 2012 on detailed XML reporting from outpatient and inpatient service performance
• http://www.msw.gov.pl/portal/pl/381/32/PESEL.html
• Nandi P., Kingskey G., Scott D.: Disease-modifying antirheumatic drugs other then methotrexate in rheumatoid arthritis and seronegative arthritis. Curr Opin Rheumatol, 2008; 20: 251-6
• Sokka T., Kautainen H., TolozaS i wsp.: QUEST-RA,: quantitative clinical assessemnet of patients with rheumatoid arthritis seen in standard rheumatolology care in 15 countries. Ann. Rheum. Dis. 2007; 66: 1491-96
• Kobelt G., Kasteng F. A raport prepared for the European Federation of Pharmaceutical industry associations (EFPIA) 2009; 2: 2

Identyfikatory

DOI

10.7365/JHPOR.2013.3.10